BIAF missed EPS expectations by 9.57%
Aug 21, 2024, 9:35 AM
0.00%
What does BIAF do
bioAffinity Technologies, Inc., headquartered in San Antonio, Texas, specializes in non-invasive diagnostics and targeted treatments for early-stage cancer, particularly lung cancer, with its lead product CyPath Lung. The company, which went public on August 26, 2022, employs 14 full-time staff and advances cancer therapeutics through its subsidiary, OncoSelect Therapeutics, LLC.
BioAffinity Technologies (BIAF) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, BioAffinity Technologies's actual EPS was -$0.19, missing the estimate of -$0.17 per share, resulting in a -9.57% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.